Abstract 8507

Article

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk DLBCL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3)

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk DLBCL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3)

N. Mounier, C. Gisselbrecht, O. Fitoussi, et al

Methods: This phase II study included 209 poor-risk diffuse large B-cell lymphoma (DLBCL) patients < 60 years (median age 49) with 2 or 3 age-adjusted International Prognostic Index (IPI) factors. Of these, 58% presented with IPI 3-5 (93% with elevated LDH and 54% with extranodal sites > 1). Four cycles of an R-ACVBP regimen was given every 15 days. Complete response and partial response patients received a consolidative BEAM regimen and peripheral blood stem cell rescue.

Results: The complete response rate (CR/CRu) after induction in 176 patients was 61%, and the partial response rate (PR) was 24%, for an ORR of 85%. For the autotransplantation population (n = 175), CR/CRu was 73% and PR was 11 (84%). Three-year progression-free survival and overall survival (PFS and OS) were estimated at 76% and 81%, respectively.

A case-controlled study matching the present R-ACVBP population with ACVBP patients selected from the LNH-98-3 trial showed 3-year PFS to be higher in the R-ACVBP group than among ACVBP patients (75% vs 58%, P = .0003). Three-year OS was estimated at 78% vs 67%, respectively (P = .05). The gain in 3-year OS was significant in patients who received auto transplantation: 89% vs 77% (P = .02).

Conclusions: These results with R-ACVBP induction and consolidative autotransplantation suggest a major survival benefit. A confirmatory prospective study is needed.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Related Content